Sanofi says Gaucher pill studies meet goals

PARIS Fri Feb 15, 2013 10:44pm IST

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company's 2012 annual results presentation in Paris February 7, 2013. REUTERS/Jacky Naegelen

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company's 2012 annual results presentation in Paris February 7, 2013.

Credit: Reuters/Jacky Naegelen

Related Topics

Stocks

   

PARIS (Reuters) - Sanofi said its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval.

Eliglustat tartrate could become the first oral treatment for Gaucher disease - a rare genetic disorder affecting some 10,000 patients - and shake up the market for therapies that currently have to be injected bi-weekly.

Eliglustat could generate annual sales of $360 million by 2017, according to ThomsonReuters Pharma forecasts.

Patients with Gaucher disease are deficient in an enzyme that breaks down a certain type of fat, leading to potentially life-threatening organ damage and bone problems.

The first study, presented at a medical congress on Friday, compared eliglustat with a placebo, while the second compared it with Cerezyme, an injectable treatment also sold by Sanofi.

Patients treated with the pill showed a "statistically significant improvement" in the size of their spleen - which typically swells as a result of Gaucher disease - without reporting serious side effects, Sanofi said.

Eliglustat also proved to be as good as Cerezyme at treating the symptoms of the disease, the drugmaker added.

Full data from the second trial will be presented at a medical meeting in the second half of 2013, Sanofi said in a statement.

A third late-stage study is currently testing whether the dosage for eliglustat could be reduced to once from twice daily.

In addition to Cerezyme, which for many years dominated the Gaucher market and was at one point the most expensive drug in the world, costing more than $200,000 a year, current treatments include Shire's Vpriv and Elelyso, sold by Pfizer.

(Reporting by Elena Berton; Editing by Christian Plumb and James Regan)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

HEALTH SHOWCASE

E-cigarettes

E-cigarettes

WHO urges stiff regulatory curbs on e-cigarettes.  Full Article 

Weighty Issues

Weighty Issues

More parents think their overweight child is 'about right'.  Full Article 

Cancer Drug

Cancer Drug

Pfizer to test Xalkori lung cancer drug with Merck immunotherapy.  Full Article 

Mental Health

Mental Health

Obama tells veterans better mental health care on the way.  Full Article 

Food Regulation

Food Regulation

Russian food safety regulator shuts fifth McDonald's restaurant.  Full Article 

Heinz Recall

Heinz Recall

Heinz recall brings food tracking issue to the fore in China.  Full Article 

Delaying Start

Delaying Start

Delay morning school start for teens: pediatricians.  Full Article 

Birth Control

Birth Control

U.S. moves to ensure birth control access at religious companies.  Full Article